Loading organizations...

§ Public · Irvine, CA, USA
Biopharmaceutical company developing bladder-sparing therapeutics for bladder cancer patients, focused on oncolytic immunotherapy.
CG Oncology is an Irvine, California-based biopharmaceutical company developing bladder-sparing therapeutics and oncolytic immunotherapies for patients with bladder cancer. The publicly traded enterprise focuses its clinical development on its lead candidate, CG0070, an oncolytic immunotherapy that targets the tumor microenvironment and is currently undergoing late-stage clinical trials. This primary therapeutic is being evaluated in combination with established oncology treatments, including Merck's Keytruda. The company went public via a reverse merger in 2021 with an approximate $150 million market capitalization, and it subsequently secured a $120 million Series E financing round in November 2022. This late-stage equity funding was backed by a syndicate of institutional investors including ORI Capital, Longitude Capital, and Decheng Capital. The organization is currently led by Chairman and Chief Executive Officer Arthur Kuan, having been originally founded as Cold Genesys in September 2010.
CG Oncology has raised $427.6M across 7 funding rounds.
CG Oncology has raised $427.6M in total across 7 funding rounds.
CG Oncology is a late-stage clinical biopharmaceutical company developing bladder‑sparing immunotherapies centered on an intravesically delivered oncolytic immunotherapy called *cretostimogene* for non‑muscle invasive bladder cancer (NMIBC).[2][4]
High-Level Overview
For a portfolio‑company style snapshot
Origin Story
Core Differentiators
Role in the Broader Tech/Medical Landscape
Quick Take & Future Outlook
Direct sources: CG Oncology corporate site and pipeline pages; public company profile summaries that document corporate history, pipeline stage, and trial identifiers.[2][4][1]
CG Oncology has raised $427.6M across 7 funding rounds. Most recently, it raised $105.0M Other Equity in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 2, 2023 | $105M Venture Round | Michael Rome, Giuliano Marostica | Acorn Bioventures, Ally Bridge Group, Avidity Partners, BVF Partners, Decheng Capital, Janus Henderson Investors, Longitude Capital, Malin Corporation, RA Capital Management | Announced |
| Aug 1, 2023 | $110M Series F | — | Foresite Capital, OrbiMed, Twenty TWO Ventures, Y Combinator, Carl Bass | Announced |
| Nov 15, 2022 | $120M Series E | Decheng Capital, Brian LIU, Simone Song | Acorn Bioventures, Ally Bridge Group, Malin Corporation, RA Capital Management, Sirona Capital | Announced |
| Dec 10, 2020 | $47M Series D | Mutsuo Kanzawa | Camford Capital, ORI Healthcare Fund, Perseverance Capital Management | Announced |
| Mar 18, 2019 | $22M Series C | Simone Song | Perseverance Capital Management | Announced |
| Aug 5, 2015 | $10M Series B | Arthur Kuan, Peter LIU | Simone Song, Whitesun Healthcare Ventures | Announced |
| Jul 30, 2014 | $13.6M Series A | David Nikodem, Ph.d. | — | Announced |
CG Oncology has raised $427.6M in total across 7 funding rounds.
CG Oncology's investors include Michael Rome, Giuliano Marostica, Acorn Bioventures, Ally Bridge Group, Avidity Partners, BVF Partners, Decheng Capital, Janus Henderson Investors, Longitude Capital, Malin Corporation, RA Capital Management, Foresite Capital.